Loading clinical trials...

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of NN1250 in Young and Geriatric Subjects With Type 1 Diabetes

NCT00964418•Novo Nordisk A/S

View on ClinicalTrials.gov

Summary

This trial is conducted in Europe. The aim of this clinical trial is to investigate the blood glucose lowering effect of NN1250 (insulin degludec) in young and elderly subjects with type 1 diabetes.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female aged 18-35 years (both inclusive) (young group) or at least 65 years (geriatric group)
•Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months
•Body mass index 18.0-28.0 kg/m\^2 (both inclusive)

Exclusion Criteria

•Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
•Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
•Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period

Locations (1)

Novo Nordisk Investigational Site

Graz, Austria

Key Dates

Start Date

August 1, 2009

Primary Completion Date

November 1, 2009

Completion Date

November 1, 2009

Last Updated

January 20, 2017

Enrollment

ACTUAL participants

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

insulin degludec

DRUG

insulin glargine

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITING

Genetic Studies of Insulin and Diabetes

NCT00001987

Diabetes MellitusSevere Insulin Resistance

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 20, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Genetic Studies of Insulin and Diabetes

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes